慢性阻塞性肺疾病的疾病进展建模
研究应用SuStaIn机器学习工具对COPDGene研究中3698例GOLD 1-4级COPD患者和3479例对照的横断面CT影像标志物进行分析,识别出两种疾病进展轨迹:Tissue→Airway亚型(70.4%)和Airway→Tissue亚型(29.6%),并在ECLIPSE数据中验证。基线分期与未来FEV1/FVC下降相关,且30%肺功能正常的吸烟者被置于较高分期,提示早期COPD影像学改变。
要点
- COPD存在两种进展亚型:Tissue→Airway(70.4%)和Airway→Tissue(29.6%)。
- 基线分期与未来FEV1/FVC下降相关(r=-0.16,P<0.001;r=-0.14,P=0.011)。
- 30%肺功能正常的吸烟者有影像学早期改变,随访时满足COPD诊断标准的可能性高2.5倍。
核心结论
- SuStaIn识别出COPD两种不同进展模式,可能代表不同内型。
- 三分之一的健康吸烟者存在可检测的影像学改变,提示早期COPD的新生物标志物。
研究设计与样本
- 应用SuStaIn机器学习工具对COPDGene研究中3698例GOLD 1-4级COPD患者和3479例对照的横断面CT影像标志物进行分析。
- 使用ECLIPSE数据确认识别的亚型和进展模式。
- 比较基线SuStaIn亚型和分期与纵向随访数据以评估患者分层效用。
主要发现
- 识别出两种疾病进展轨迹:Tissue→Airway亚型(n=2354,70.4%)和Airway→Tissue亚型(n=988,29.6%)。
- 亚型在ECLIPSE中可重复。
- 两种亚型的基线分期与未来FEV1/FVC下降相关(Tissue→Airway组r=-0.16,P<0.001;Airway→Tissue组r=-0.14,P=0.011)。
- SuStaIn将30%肺功能正常的吸烟者置于较高分期,提示影像学改变与早期COPD一致。
- 有早期改变的个体在随访时满足COPD诊断标准的可能性高2.5倍。
临床怎么用
- SuStaIn可用于COPD患者分层,识别不同进展轨迹。
- 影像学早期改变可能作为早期COPD的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The decades-long progression of chronic obstructive pulmonary disease (COPD) renders identifying different trajectories of disease progression challenging.Objectives: To identify subtypes of patients with COPD with distinct longitudinal progression patterns using a novel machine-learning tool called "Subtype and Stage Inference" (SuStaIn) and to evaluate the utility of SuStaIn for patient stratification in COPD.Methods: We applied SuStaIn to cross-sectional computed tomography imaging markers in 3,698 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1-4 patients and 3,479 controls from the COPDGene (COPD Genetic Epidemiology) study to identify subtypes of patients with COPD. We confirmed the identified subtypes and progression patterns using ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) data. We assessed the utility of SuStaIn for patient stratification by comparing SuStaIn subtypes and stages at baseline with longitudinal follow-up data.Measurements and Main Results: We identified two trajectories of disease progression in COPD: a "Tissue→Airway" subtype (n = 2,354, 70.4%), in which small airway dysfunction and emphysema precede large airway wall abnormalities, and an "Airway→Tissue" subtype (n = 988, 29.6%), in which large airway wall abnormalities precede emphysema and small airway dysfunction. Subtypes were reproducible in ECLIPSE. Baseline stage in both subtypes correlated with future FEV1/FVC decline (r = -0.16 [P < 0.001] in the Tissue→Airway group; r = -0.14 [P = 0.011] in the Airway→Tissue group). SuStaIn placed 30% of smokers with normal lung function at elevated stages, suggesting imaging changes consistent with early COPD. Individuals with early changes were 2.5 times more likely to meet COPD diagnostic criteria at follow-up.Conclusions: We demonstrate two distinct patterns of disease progression in COPD using SuStaIn, likely representing different endotypes. One third of healthy smokers have detectable imaging changes, suggesting a new biomarker of "early COPD."
引用
- Young AL, Bragman FJS, Rangelov B, et al. Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020. PMID: 31657634. doi:10.1164/rccm.201908-1600OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。